semaglutide update Troubling Findings in Study of GLP-1 Compounders Novo Nordisk announced headline results

Modern liver-specific IGF-1 knockout studies have shown that local IGF-1 contributes substantially to tissue IGF1R activation, separate from the endocrine pool

Tirzepatide, a dual GIP and GLP-1 receptor agonist approved by the FDA for type 2 diabetes and chronic weight management, modulates hunger signals rather than eliminating them entirely

Doing so can increase the risk of side effects like low blood sugar (especially if combined with other diabetes medications) or gastrointestinal upset

Semaglutide was initiated at a dose of 0.25 mg weekly for the first month, 0.5 mg weekly during the second month, and then increased to 1 mg weekly

Pylori infections damage intestinal structures responsible for B12 absorption

For example, dysregulation of the NLRP3-Caspase 1 signaling pathway caused by ES, was reversed by nutritional interventions wit proanthocyanidins [53]